Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — SUO Annual Meeting (SUO25) 2025
13 slides from Cg Oncology's conference presentation, Dec 5, 2025
Slide 1: Topline Results From BOND-003 Cohort P: Intravesical Cretostimogene Grenadenorepvec
Topline Results From BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene For individual reference only. The information accessed Grenadenorepvec for Treatment of High- through this QR code is intended solely for individual reference and should not be altered, modifie
Slide 2: Disclosures
Disclosures • CG Oncology- No Conflicts of Interest ©2022 Mayo Foundation for Medical Education and Research | slide-2
Slide 3: Cretostimogene Grenadenorepvec Selectively Targets Rb-E2F Pathway Altered Cancers
Cretostimogene Grenadenorepvec Selectively Targets Rb-E2F Pathway Altered Cancers • Conditionally replicating, highly immunogenic adenovirus oUnder regulation of the human E2F-1 promoter - Selective for RB-E2F pathway alterations oEncodes GM-CSF transgene • Oncolytic immunotherapy with dual MOA oVir
Slide 4: Significant Unmet Need for BCG-UR Papillary (HG Ta/T1) NMIBC
Significant Unmet Need for BCG-UR Papillary (HG Ta/T1) NMIBC DFS/HG-RFS Pembrolizumab 5 Nadofaragene 6,7 N-803+BCG 8 TAR-200 9 • Current FDA approved agents for patients with HR BCG-UR 3 months, % 87.7 72.9 Not Reported Not Reported (95% CI) (80.7-92.3) (58.2-84.7) NMIBC with CIS +/- Ta/T11 6 months
Slide 5: Consistent and Compelling CR & Durability Data
Consistent and Compelling CR & Durability Data Overall Complete Response CR CR Rate, % CR by K-M Est, % 75.5% 100 Landmark (95% CI) (95% CI) (95% CI, 66.3 % - 83.2 %) 12-month 46.4% (36.9, 56.1) 50.7% (40.9, 59.8) Overall CR Rate (%) 75 51 out of 110 patients 41.8% (32.5, 51.6)1 24-month 42.4% (32.7
Slide 6: BOND-003 Cohort P- Papillary Only (HG Ta/T1), BCG-UR, HR-NMIBC
BOND-003 Cohort P- Papillary Only (HG Ta/T1), BCG-UR, HR-NMIBC Cohort C (N=112): Primary Endpoint: Cohort P (N=56): Primary Endpoint: • Age ≥ 18 yo • CR at any time • Age ≥ 18 yo • HG-EFS • ECOG PS 0-2 • Pathologically confirmed • Pathologically confirmed Secondary HR BCG-UR NMIBC HG Ta/T1 (Without
Slide 7: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics Patients in Safety Dataset N=56 % Gender Male 44 78.6 Female 12 21.4 Age (Years) • Majority of patients are: Mean (SD) 71.6 (9.3) o Male (78.6%) Median (Range) 74.0 (45-87) Age (Categories) o White (87.5%) < 65 13 23.2 o > 65 years (75%) ≥ 65 and < 75
Slide 8: Topline Results: BOND-003 Cohort P HR, Papillary-Only BCG-Unresponsive NMIBC
Topline Results: BOND-003 Cohort P HR, Papillary- Only (HG Ta/T1) BCG-Unresponsive NMIBC Kaplan-Meier Estimate for • Median follow-up was 6.0 months High Grade Event-Free Survival HG Recurrence-Free Survival (%) • 8 patients were re-induced • Consistent and high HG-EFS HG Event -Free Survival (%) •
Slide 9: Consistent, Favorable and Well-Tolerated Safety Profile from BOND-003 Cohort P
Consistent, Favorable and Well-Tolerated Safety Profile from BOND-003 Cohort P Cretostimogene (n=56) Preferred Term (MedDRA v.26.1) • Most AEs were Grade 1-2 Any Grade (%) Grade ≥ 3 • 0% Grade ≥ 3 TRAEs, Serious TRAE, Patients with ≥ 1 TRAE 40 (71.4%) 0 (0) deaths Treatment-Related AE reported in >
Slide 10: BOND-003 Cohort P: Conclusions
BOND-003 Cohort P: Conclusions • Topline results with cretostimogene in BOND-003 Cohort P consistently demonstrate o Strong HG-EFS at 3, 6, and 9 mo o Responses maintained across HGTa and higher-risk, HGT1, populations o Well-tolerated safety profile • Longer-term treatment and follow up ongoing ©20
Slide 11: Initiated BLA Submission to US FDA for HR BCG-UR NMIBC with CIS +/- Ta/T1
Initiated BLA Submission to US FDA for HR BCG-UR NMIBC with CIS +/- Ta/T1! ©2024 Mayo Foundation for Medical Education and Research | slide-11
Slide 12: Acknowledgements
Acknowledgements Top 30 Abstracts All Bladder Cancer Patients and Their Families The Study Coordinators and Nurses Key Collaborators CG Oncology Paras Shah, Mayo Clinic, Rochester, MN Andy Darilek Timothy Lyon, Mayo Clinic, Jacksonville, FL Jee-Hyun Kim Ankeet Shah, Duke, Durham, NC Pat Keegan Trini
Slide 13: Thank You & Questions
Thank You & Questions For individual reference only. The information accessed through this QR code is intended solely for individual reference and should not be altered, modified, or reproduced in any way. ©2022 Mayo Foundation for Medical Education and Research | slide-13